Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has been given a consensus rating of “Hold” by the ten brokerages that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $5.35.
ACHN has been the subject of several recent research reports. BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 16th. ValuEngine cut Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, September 11th. Robert W. Baird reissued a “neutral” rating and issued a $4.00 price target (down previously from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. Ladenburg Thalmann Financial Services lowered their price target on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating for the company in a research note on Tuesday, September 12th. Finally, Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 14th.
In related news, major shareholder & Johnson Johnson sold 18,367,346 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $2.75, for a total value of $50,510,201.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.24% of the stock is owned by insiders.
Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) opened at $2.89 on Thursday. Achillion Pharmaceuticals has a 12 month low of $2.80 and a 12 month high of $5.66.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.04. During the same period in the prior year, the firm posted ($0.15) earnings per share. analysts forecast that Achillion Pharmaceuticals will post -0.63 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/12/14/achillion-pharmaceuticals-inc-achn-receives-consensus-recommendation-of-hold-from-analysts.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.